Literature DB >> 33238815

Terminology Change for Small Low-Risk Papillary Thyroid Cancer As a Response to Overtreatment: Results from Three Australian Community Juries.

Patti Shih1, Brooke Nickel2,3, Chris Degeling1, Rae Thomas4, Juan P Brito5, Donald S A McLeod6,7, Kirsten McCaffery2,3, Stacy M Carter1.   

Abstract

Background: The majority of small papillary thyroid cancers (sPTCs) are treated surgically, rather than by active surveillance. Patient and clinician preference for surgery may be partially driven by the use of cancer terminology. Some experts propose that changing terminology would better communicate the indolent nature of sPTCs and improve uptake of active surveillance. Others argue that terminology that includes "cancer" correctly reflects the biological nature of these tumors. The views of informed lay publics can provide value-based perspectives on complex issues and guide policy discussions.
Methods: We recruited 40 people for three community juries, held in Sydney, Wodonga, and Cairns, Australia. Participants were of diverse backgrounds and ages, recruited through random digit dialing and a topic-blinded social media strategy. Juries were informed about thyroid cancer, overdiagnosis, and overtreatment, and heard arguments for and against terminology change before deliberation. The deliberative process in Jury 1 led to a refinement of jury charge, the updated version that was then used in Juries 2 and 3.
Results: Jury 1 favored no terminology change, and Juries 2 and 3 were divided on the topic. Key reasons for opposing terminology change included a strong desire to retain terminology that aligns with the pathological definition of cancer, and to avoid even a minimal risk of harm that could arise if patients became complacent in follow-up. Key reasons to support terminology change included a desire to reduce psychological distress, stigma, and discrimination associated with a cancer diagnosis, and an argument that terminology change may be a more effective trigger for health system reform compared with other options. The juries unanimously recommended community education and health system reforms to reduce harms of overtreatment, and expressed an expectation that clinicians and researchers reach agreement on clinical guidelines to promote better uptake of active surveillance. Conclusions: The conceptual tension between a pathological and an outcome-based understanding of cancer was apparent in deliberation. This highlights an ongoing challenge for those advocating changing disease terminology. Regardless of action on terminology, jurors shared a strong expectation that practical changes would be made to respond to the harms of overtreatment.

Entities:  

Keywords:  Australia; community jury; nomenclature revision; overdiagnosis; papillary thyroid cancer

Mesh:

Year:  2021        PMID: 33238815     DOI: 10.1089/thy.2020.0694

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  3 in total

Review 1.  Patient perception of receiving a thyroid cancer diagnosis.

Authors:  Catherine B Jensen; Susan C Pitt
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2021-10-01       Impact factor: 3.626

2.  What's in a Name? A Cost-Effectiveness Analysis of the Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features' Nomenclature Revision.

Authors:  Vikas Mehta; Ankita Naraparaju; David Liao; Louise Davies; Bryan R Haugen; Peter A Kopp; Susan J Mandel; Yuri E Nikiforov; Douglas S Ross; Jennifer J Shin; R Michael Tuttle; Gregory W Randolph
Journal:  Thyroid       Date:  2022-01-07       Impact factor: 6.506

Review 3.  Active Surveillance of Thyroid Microcarcinomas: a Critical View.

Authors:  Claudio R Cernea; Leandro Luongo Matos; Cecília Eugênio; Giovanna Mattos Ferreira; Yasmin Sa Cerqueira; Ana Kober N Leite; Felipe A B Vanderlei; Dorival de Carlucci; Renato N Gotoda; Flávio C Hojaij; Vergilius J F Araújo-Filho
Journal:  Curr Oncol Rep       Date:  2022-01-21       Impact factor: 5.075

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.